CLAIMS

[Claim 1]

An oral pharmaceutical composition in the form of a dry syrup comprising: ART-001 (serabelisib); an inorganic or organic acid; and a hydrophilic polymer.

[Claim 2]

The oral pharmaceutical composition according to claim 1, wherein the inorganic or organic acid is one or more acids selected from phosphoric acid, hydrochloric acid, citric acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, succinic acid, aspartic acid, lactic acid, acetic acid, glutamic acid, and adipic acid.

[Claim 3]

The oral pharmaceutical composition according to claim 1 or 2, wherein the inorganic or organic acid is one or more acids selected from phosphoric acid, citric acid, tartaric acid, and glutamic acid.

[Claim 4]

The oral pharmaceutical composition according to any one of claims 1 to 3, wherein the hydrophilic polymer is one or more polymers selected from polyvinyl alcohol, povidone, hypromellose, copovidone, hydroxypropylcellulose, polyvinyl alcohol-polyethylene glycol-graft copolymer, hypromellose phthalate, and hypromellose acetate succinate.

[Claim 5]

The oral pharmaceutical composition according to any one of claims 1 to 4, wherein the content percentage of ART-001 (serabelisib) is from 2 to 40 mass %

[Claim 6]

The oral pharmaceutical composition according to any one of claims 1 to 5, wherein the content ratio of the inorganic or organic acid to one mass part of ART-001 (serabelisib) is from 0.1 to 10 mass parts.

[Claim 7]

The oral pharmaceutical composition according to any one of claims 1 to 6, wherein the content ratio of the hydrophilic polymer to one mass part of ART-001 (serabelisib) is from 0.02 to 5 mass parts.

[Claim 8]

A method of producing an oral pharmaceutical composition according to any one of claims 1 to 7, comprising: wet-granulating a mixture containing ART-001 (serabelisib), the inorganic or organic acid, and the hydrophilic polymer, and drying the granulated product.